long intergenic non-protein coding RNA 1346Genealiases: []
Q-omics provides the consensus-scored LINC01346 profile across patient tissues and cancer cell-line models. LINC01346 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01346 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, LINC01346 RNA expression shows 7,033 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where LINC01346 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01346 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01346 survival associations across molecular data types. LINC01346 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01346 RNA expression–survival associations across cancer types. High LINC01346 expression shows unfavorable associations in KIRC, ACC, DLBC, TGCT and HNSC, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01346 RNA expression.
This table summarizes LINC01346 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01346. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01346 shows lower tumor expression in BLCA, PRAD and READ and higher tumor expression in COAD and LIHC. The COAD box plot shows higher LINC01346 RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .004).
This table shows molecular features associated with LINC01346 in patient tissues and cancer cell lines. In patient samples, LINC01346 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
